1 / 38

Hepatitis B Virus and Cancer Everett Schlam, MD 9/22/2011

Hepatitis B Virus and Cancer Everett Schlam, MD 9/22/2011. Pick any number between 2 and 10 Multiply that number x 9 Add the two digits of that number together Subtract 5 from that number Pick the letter which corresponds to that number in the alphabet Ie, A=1 B=2 C=3 D=4

chanel
Download Presentation

Hepatitis B Virus and Cancer Everett Schlam, MD 9/22/2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis B Virus and CancerEverett Schlam, MD9/22/2011

  2. Pick any number between 2 and 10 • Multiply that number x 9 • Add the two digits of that number together • Subtract 5 from that number • Pick the letter which corresponds to that number in the alphabet Ie, A=1 B=2 C=3 D=4 • Pick a country which begins with that letter. • Now take the second letter of that country and choose a large animal which begins with that letter

  3. Viral Hepatitis 5 types: A: fecal-oral transmission B: sexual fluids & blood to blood C: blood to blood D: travels with B E: fecal–oraltransmission Vaccine Preventable Adapted from Corneil, 2003

  4. Hepatitis B • Epidemic jaundice described by Hippocrates in 5th century BC • Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s • Australia antigen described in 1965 • Serologic tests developed in 1970s

  5. Hepatitis B Complications • Fulminant hepatitis • Hospitalization • Cirrhosis • Hepatocellular carcinoma • Death

  6. Hepatitis B Virus Infection • More than 350 million chronically infected worldwide • Established cause of chronic hepatitis and cirrhosis • Human carcinogen—cause of up to 80% of Hepatocellular carcinomas • More than 600,000 deaths worldwide in 2002

  7. Only 20% will show symptoms Initially ! Natural History of Hep C 20% Clear the Virus Chronic Infection Acute Infection Healthy Liver 80% Virus Continues to Damage Liver Adapted from Lauer and Walker, NEJM 2001

  8. Natural History Con’t Liver Cancer 1-4%/year Cirrhosis 20-30% Chronic Hepatitis Most symptoms begin to show only when liver is more severely damaged

  9. Factors Affecting Progression • 30yrs or longer if: • Young at time of infection • Healthy liver at time of infection • Female • 20yrs or less if: • Drinking alcohol • Co-infection (HIV, Hep B) • Damaged liver before infection Adapted from Bigham, BC Hepatitis Services 2002

  10. IDU/snorting (51%) No RF identified (23%) Incarceration (3%) Transfusion/dialysis blood contact (4%) HCV-infected household member/sexual partner (7%) Hospitalization dental work (6%) Tattooing piercing (6%) Risk Factors Source: Health Canada Enhanced Surveillance, Oct 98-Oct 99, Calgary, Edmonton, Winnipeg, Ottawa

  11. Overall cure rate with new treatment is 55% * Hepatitis C • Affects each person differently • No vaccine available • Many people have the virus and do not even know it *BC Hepatitis Service 2003

  12. Hepatitis C Dispelling Myths • Hepatitis C is not spread by: • Casual contact • Hugging/kissing • Sharing eating utensils and drinking glasses • Sneezing/coughing • Shaking hands • Sitting on a toilet seat

  13. HBV Disease Burden in the United States • Pre-vaccine era • estimated 300,000 persons infected annually, including 24,000 infants and children • 2005 • estimated 51,000 infections • Overall cure rate about 55%

  14. Hepatitis B Perinatal Transmission* • If mother positive for HBsAg and HBeAg • 70%-90% of infants infected • 90% of infected infants become chronically infected • If positive for HBsAg only • 5%-20% of infants infected • 90% of infected infants become chronically infected *in the absence of postexposure prophylaxis

  15. Who should be vaccinated with Hepatitis B Vaccine ?

  16. Strategy to Eliminate Hepatitis B Virus Transmission—United States • Prevent perinatal HBV transmission • Routine vaccination of all infants • Vaccination of children in high-risk groups • Vaccination of adolescents • Vaccination of adults in high-risk groups

  17. Risk Factors for Hepatitis B CDC Sentinel Sites. 2001 data.

  18. Hepatitis B VaccineLong-term Efficacy • Immunologic memory established following vaccination • Exposure to HBV results in anamnestic anti-HBs response • Chronic infection rarely documented among vaccine responders

  19. Adults at Risk for HBV Infection • Sexual exposure • sex partners of HBsAg-positive persons • sexually active persons not in a long-term, mutually monogamous relationship* • persons seeking evaluation or treatment for a sexually transmitted disease • men who have sex with men *persons with more than one sex partner during the previous 6 months

  20. Adults at Risk for HBV Infection • Percutaneous or mucosal exposure to blood • current or recent IDU • household contacts of HBsAg-positive persons • residents and staff of facilities for developmentally disabled persons • healthcare and public safety workers with risk for exposure to blood or blood-contaminated body fluids • persons with end-stage renal disease

  21. Who should have Hepatitis B screening Tests?

  22. Prevaccination Serologic Testing • Not indicated before routine vaccination of infants or children • Recommended for • all persons born in Africa, Asia, the Pacific Islands, and other regions with HBsAg prevalence of 8% or higher • household, sex, and needle-sharing contacts of HBsAg-positive persons • HIV-infected persons • Consider for • Groups with high risk of HBV infection (MSM, IDU, incarcerated persons)

  23. What are the recommended serological screening tests for Hepatitis B?

  24. Screening Tests for Hepatitis B • HBsAg • Anti-HBs • Cost for both tests about (150-250 dollars) • Further testing and treatment determined by results of HBsAG and Anti-HBs

  25. Chronic Inactive Hepatitis B Infection • Surveillance monitoring for reactivation

  26. Chronic Active Hepatitis B Treatment Options • Interferons • Interferon alfa-2b • Peginterferon alfa 2-b • Nucleotids(t)ide analogs • Lamivudine • Adenovir • Entecavir • Telbivudine • Tenofovir

  27. Who is post vaccination serological testing recommended for and when should the testing be performed?

  28. Postvaccination Serologic Testing • Not routinely recommended following vaccination of infants, children, adolescents, or most adults • Recommended for: • Infants born to HBsAg+ women • Hemodialysis patients • Immunodeficient persons • Sex partners of persons with chronic HBV infection • Certain healthcare personnel

  29. Healthcare personnel who have contact with patients or blood should be tested for anti-HBs (antibody to hepatitis B surface antigen) 1 to 2 months after completion of the 3-dose series Postvaccination Serologic Testing

  30. Management of Nonresponse to Hepatitis B Vaccine • Complete a second series of three doses • Should be given on the usual schedule of 0, 1 and 6 months • Retest 1-2 months after completing the second series

  31. Persistent Nonresponse to Hepatitis B Vaccine • Less than 5% of vaccinees do not develop anti-HBs after 6 valid doses • May be nonresponder or "hyporesponder" • Check HBsAg status • If exposed, treat as nonresponder with postexposure prophylaxis

  32. Needle Prick • Do not “milk” prick site • Wash the area with soap and water • Go to nearest emergency department for assessment and treatment

  33. Chronic Hepatitis B and risk of Hepatocellular Cancer • Hepatocellular Cancer occurs in up to 25% of men and 15% of women over their lifetimes

  34. Hepatitis B and Cancer • Hepatocellular Cancer is a devastating complication of Hepatitis B • Prevention is the optimal strategy to prevent acquisition of Hepatitis B • Immunization and avoidance of high risk activities are of upmost importance

  35. Questions??

More Related